荃信生物－Ｂ与罗氏达成QX031N的全球独家许可协议

Core Insights - The company announced a global exclusive collaboration and licensing agreement with F. Hoffmann-La Roche Ltd for the development, production, and commercialization of QX031N [1] Financial Details - The company will receive a one-time, non-refundable, and non-deductible upfront payment of $75 million [1] - The company is eligible for up to $995 million in milestone payments related to product development, regulatory approval, and commercialization [1] - There are potential future sales royalties based on product sales [1]